AR109451A1 - Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión - Google Patents
Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresiónInfo
- Publication number
- AR109451A1 AR109451A1 ARP170101019A ARP170101019A AR109451A1 AR 109451 A1 AR109451 A1 AR 109451A1 AR P170101019 A ARP170101019 A AR P170101019A AR P170101019 A ARP170101019 A AR P170101019A AR 109451 A1 AR109451 A1 AR 109451A1
- Authority
- AR
- Argentina
- Prior art keywords
- rrs
- vector
- nucleic acid
- vectors
- different
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109451A1 true AR109451A1 (es) | 2018-12-12 |
Family
ID=58701851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101019A AR109451A1 (es) | 2016-04-20 | 2017-04-20 | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (OSRAM) |
| EP (1) | EP3445781A1 (OSRAM) |
| JP (3) | JP7096770B2 (OSRAM) |
| KR (2) | KR20230098361A (OSRAM) |
| CN (2) | CN109195986B (OSRAM) |
| AR (1) | AR109451A1 (OSRAM) |
| AU (2) | AU2017253241B2 (OSRAM) |
| BR (1) | BR112018071283A2 (OSRAM) |
| CA (1) | CA3015389A1 (OSRAM) |
| EA (1) | EA201892010A1 (OSRAM) |
| IL (2) | IL314779A (OSRAM) |
| MX (2) | MX2018012868A (OSRAM) |
| SG (2) | SG10202010155YA (OSRAM) |
| TW (2) | TW202415767A (OSRAM) |
| WO (1) | WO2017184832A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202010155YA (en) * | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| CA3123448A1 (en) * | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Targeted integration of nucleic acids |
| TWI851703B (zh) * | 2019-04-02 | 2024-08-11 | 日商中外製藥股份有限公司 | 標的特異性外源基因的導入方法 |
| JP7720787B2 (ja) * | 2019-06-26 | 2025-08-08 | ジェネンテック， インコーポレイテッド | 核酸のランダム化された構成標的化組込み |
| EP4419698A1 (en) | 2021-10-18 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| TW202330926A (zh) | 2021-10-18 | 2023-08-01 | 美商再生元醫藥公司 | 聚核苷酸之受控制轉錄 |
| WO2023122246A1 (en) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| JPWO2023238949A1 (OSRAM) * | 2022-06-10 | 2023-12-14 | ||
| WO2025054526A1 (en) | 2023-09-07 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| JP4817657B2 (ja) | 2002-05-29 | 2011-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 誘導性の真核生物発現システム |
| WO2004046340A2 (en) | 2002-11-14 | 2004-06-03 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| US7771997B2 (en) | 2007-06-04 | 2010-08-10 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CN102459603B (zh) * | 2009-06-02 | 2013-11-06 | 瑞泽恩制药公司 | 岩藻糖基化缺陷型细胞 |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| JP6091894B2 (ja) | 2009-09-16 | 2017-03-15 | ジェネンテック， インコーポレイテッド | コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用 |
| SG178940A1 (en) * | 2009-09-18 | 2012-04-27 | Selexis Sa | Products and methods for enhanced transgene expression and processing |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015335921B2 (en) | 2014-10-23 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Novel CHO integration sites and uses thereof |
| PT3353212T (pt) | 2015-09-23 | 2022-01-05 | Regeneron Pharma | Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações |
| SG10202010155YA (en) * | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
-
2017
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 KR KR1020237020953A patent/KR20230098361A/ko active Pending
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 IL IL262266A patent/IL262266B2/en unknown
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en not_active Ceased
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt unknown
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active Active
-
2018
- 2018-10-19 MX MX2025003852A patent/MX2025003852A/es unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US20230130799A1/en active Pending
-
2023
- 2023-11-29 JP JP2023201924A patent/JP7781128B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| CL2021002742A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| PH12021553042A1 (en) | Sorting with counter selection using sequence similar peptides | |
| TN2018000325A1 (en) | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123. | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| ECSP22015276A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
| MX385857B (es) | Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente. | |
| TN2019000015A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| EP4223873A3 (en) | Compositions and methods for t cell delivery of therapeutic molecules | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| MX2020003339A (es) | Arn guía de cpf1 modificado. | |
| MX2021000934A (es) | Linfocitos t que contienen nef y métodos para producirlos. | |
| AR102092A1 (es) | Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii) | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| MY202687A (en) | Pharmaceutical chimeric receptor composition and method thereof | |
| MX2025004565A (es) | Anticuerpos anti-cd3 dependientes de ph y metodos relacionados con estos | |
| CY1123363T1 (el) | Απομονωση νουκλεϊνικων οξεων | |
| EA202091713A1 (ru) | Биологический синтез аминокислотных цепей для получения пептидов и белков | |
| EA202193234A1 (ru) | Сортировка с контрселекцией с применением пептидов со сходными последовательностями | |
| Faridi | Solving the spliced-peptides mystery by using machine learning techniques | |
| EA202192299A1 (ru) | Библиотеки вариантных нуклеиновых кислот для оптимизации антител |